Novel lipid-based adjuvants for induction of mucosal immunity

用于诱导粘膜免疫的新型脂质佐剂

• 批准号: LP0455698
• 负责人: Prof Kenneth Beagley
• 金额: $ 7.11万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-04-21 至 2009-06-13
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0455698
• 关键词: Novel; lipid; based; adjuvants; induction

The project will determine if needle-free oral and transcutaneous immunisation using LipoVax, a novel lipid-based antigen delivery system developed by the industry partner, can protect mice against the mucosal pathogens Chlamydia and Helicobacter. We expect to show that this immunisation method can induce protective mucosal immunity against two of the most common infectious organisms affecting mankind. If successful this will allow us to develop LipoVax as a new platform technology that can be applied to the development of human vaccines, veterinary vaccines, vaccines for companion animals and vaccines to target infections in feral animals and native wildlife population populations.

该项目将确定使用LipoVax的无针口服和经皮免疫接种是否可以保护小鼠免受黏膜病原体衣原体和幽门螺杆菌的侵袭。LipoVax是一种由该行业合作伙伴开发的新型基于脂质的抗原递送系统。我们希望证明这种免疫方法可以诱导保护性粘膜免疫，以抵御影响人类的两种最常见的传染病。如果成功，这将使我们能够将LipoVax开发为一种新的平台技术，可应用于开发人类疫苗、兽用疫苗、同伴动物疫苗以及针对野生动物和本地野生动物种群感染的疫苗。